Phylogica Limited is an Australia-based company. The Company is engaged in provision of drug discovery services to the international pharmaceutical industry utilizing the Company�s Phylomer peptide libraries and screening capabilities. The Company is engaged in the discovery of peptide-based drugs to treat inflammatory diseases. The Company operates in a single geographical location being Australia. These natural peptides are based on expressed sequences of protein fragments that are encoded by the genes of evolutionary diverse microbes and they thus represent a new class of biological therapeutics. Phylomer peptides display structural stability, specificity and affinity, thereby giving them the potential to address disease targets that are intractable to small molecules and other protein biologics including antibodies. The Company has an intellectual property portfolio around its Phylomer peptide libraries and associated technology.